Show simple item record

FieldValueLanguage
dc.contributor.authorBell, Katy J.L.
dc.contributor.authorDoust, Jenny
dc.contributor.authorGlasziou, Paul
dc.date.accessioned2021-02-18T23:48:33Z
dc.date.available2021-02-18T23:48:33Z
dc.date.issued2018en
dc.identifier.urihttps://hdl.handle.net/2123/24537
dc.description.abstractThe recent recommendations from the American College of Cardiology and the American Heart Association (ACC/AHA) to lower the thresholds for defining hypertension and for treating higher-risk patients1 have been controversial. For example, the Clinical Guidelines Committee of the American College of Physicians (ACP) argued that the changes are “not supported by evidence and may result in low-value care,” and the American Academy for Family Physicians (AAFP) raised concerns that the “harms of treating a patient to a lower blood pressure (BP) were not assessed.” The Table summarizes key differences between the ACC/AHA guideline and prior guidelines.en
dc.language.isoenen
dc.publisherAmerican Medical Associationen
dc.relation.ispartofJAMA Internal Medicineen
dc.rightsCopyright All Rights Reserveden
dc.subjectblood pressureen
dc.subjecthypertensionen
dc.subjectguidelinesen
dc.titleIncremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline.en
dc.typeArticleen
dc.subject.asrc1102 Cardiorespiratory Medicine and Haematologyen
dc.subject.asrc1117 Public Health and Health Servicesen
dc.identifier.doi10.1001/jamainternmed.2018.0310
dc.relation.nhmrc527500
dc.relation.nhmrc1104136
usyd.facultySeS faculties schools::Faculty of Medicine and Health::Sydney School of Public Healthen
usyd.citation.volume178en
usyd.citation.issue6en
usyd.citation.spage755en
usyd.citation.epage757en
workflow.metadata.onlyNoen


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

There are no previous versions of the item available.